🔗 Visit the ClinicalTrials.gov page for NCT00349934
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Combination cancer immunotherapies tailored to the tumour microenvironment. | Nat Rev Clin Oncol | 2015 | 1.54 |
| 2 | First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. | J Transl Med | 2010 | 1.01 |
| 3 | Immune checkpoint inhibitors in clinical trials. | Chin J Cancer | 2014 | 0.98 |
| 4 | Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. | Immunotherapy | 2015 | 0.81 |
| 5 | Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity. | Oncoimmunology | 2014 | 0.81 |
| 6 | Lymphocyte-activation gene-3, an important immune checkpoint in cancer. | Cancer Sci | 2016 | 0.76 |